Resources
A look at how GenXMap turns raw sequencing data into a documented, decision-ready scientific report: plus platform updates and answers to the questions we hear most before a project starts.
Case studies
Illustrative case studies showing how each Xplorer programme is designed, run and interpreted, from study design to biological evidence. They do not describe client projects; figures are indicative.
A worked example on a synthetic dataset, not a real study: QC, PCA, differential expression and functional enrichment for a dermo-cosmetic active on skin explants.
Illustrative study: Biomarker Xplorer combines WGS, WES and RNA-seq for discovery with targeted assays for confirmation, from 21,400 features to a locked 7-marker score.
Illustrative study: Microbiome Xplorer follows a probiotic from strain engraftment to microbial functions, metabolites and the host, and shows where the chain breaks.
Illustrative study: Skin Biology Xplorer combines 2D cells, 3D skin and explants with multi-omics to map a mechanism of action and the claims it can support.
Blog & news
Notes on methodology, platform updates and news from GenXMap's R&D programs, publishing soon.
Methodology notes, platform updates and R&D news will be published here as they're ready.
FAQ
Common questions before starting a project. Don't see yours, write to us directly.
Blood, tissue, cells, FFPE, saliva, plasma, stool, bacteria and skin explants, among others: sample preparation and extraction are optimized by sample type. Tell us what you have and we'll confirm feasibility.
No fixed minimum: every project is scoped individually, from a single pilot study to a multi-year research partnership. Tell us your sample volume and biological question and we'll confirm what's feasible.
Yes. Our Genomics & Multi-Omics platform covers both bulk and single-cell RNA-seq, alongside whole genome, whole exome and targeted sequencing.
Turnaround depends on the platform and sample volume, and is confirmed upfront during scoping. Across our track record, 95% of projects are delivered on the agreed schedule.
A documented, decision-ready report: QC metrics, figures, statistical results and biological interpretation, plus raw and processed data. Interactive dashboards are available on request rather than a static PDF only.
Yes. OMICS4, powered by GenXMap, covers the wet-lab platforms (sample processing, molecular biology, genomics & multi-omics, imaging) independently. GenXMap's Computational Biology & AI team can also analyze data you've generated elsewhere.
Yes. Our Computational Biology & AI team can take FASTQ files or other processed data you already have and run further analysis, quality control or multi-omics integration on it.
Yes, academic and hospital labs, biotech and pharma teams, and translational research groups. See Outsourced & Collaborative R&D for how we adapt to each.
Generally yes, tell us your sample type and country of origin and we'll confirm shipping logistics and any import requirements before you send anything.
We're happy to sign a mutual confidentiality agreement before discussing project specifics, just ask when you write to us.
Yes. Projects are covered by mutual confidentiality agreements, and data handling follows enterprise-grade security practices throughout.
Write to us with your sample type and biological question. We'll recommend the right platform(s) and provide a quote.